Welcome to our dedicated page for PEAR news (Ticker: PEAR), a resource for investors and traders seeking the latest updates and insights on PEAR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PEAR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PEAR's position in the market.
Pear Therapeutics, Inc. (NASDAQ: PEAR) has filed for Chapter 11 bankruptcy protection, seeking to sell its business or assets under section 363 of the Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware, following an evaluation of strategic alternatives to maximize stakeholder value. The company has significantly reduced operating expenses and plans to continue limited operations during the bankruptcy process. They have reached a settlement with their lender to fund post-petition operations and intend to file motions for customary relief to ensure a smooth transition into Chapter 11.
Pear Therapeutics, Inc. (NASDAQ: PEAR), a leader in developing prescription digital therapeutics (PDTs), is exploring strategic alternatives to maximize shareholder value. The company has engaged MTS Health Partners as its exclusive financial advisor for this process, which may include potential acquisitions, mergers, or additional financing. No definitive timeline is set, and the outcome remains uncertain. If Pear fails to secure a favorable transaction, it may face reorganization or liquidation. The company emphasizes the importance of this strategic review for maintaining operations and shareholder interests.
Pear Therapeutics, Inc. (NASDAQ: PEAR) will participate in the 43rd Annual Cowen Healthcare Conference from March 6-8, 2023, in Boston. President and CEO, Corey McCann, M.D., Ph.D., will engage in an analyst-led fireside chat on March 6 at 9:10 a.m. ET. A live audio webcast can be accessed here and will be available on Pear's website for up to 30 days post-event. Pear Therapeutics is a leader in prescription digital therapeutics (PDTs), with a pipeline that includes FDA-authorized treatments for substance use disorder and chronic insomnia.
Pear Therapeutics, Inc. (Nasdaq: PEAR), a leader in developing prescription digital therapeutics (PDTs), announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023, in Snowbird, UT. Pear's management will engage in virtual 1x1 meetings during the event. As the first company to receive FDA marketing authorization for PDTs, Pear's products include reSET® for substance use disorder, reSET-O® for opioid use disorder, and Somryst® for chronic insomnia. Pear focuses on innovative, clinically validated software-based medicines to improve patient outcomes and reduce costs for payers.
Pear Therapeutics (NASDAQ: PEAR) announced an expansion of its collaboration with BrightView Health, enabling greater access to its prescription digital therapeutics—reSET® and reSET-O®—in Kentucky, Ohio, Delaware, Massachusetts, and Virginia. BrightView, a leader in outpatient addiction treatment, began piloting these products in early 2022 and now aims to extend their use to support adults suffering from substance use disorder (SUD) and opioid use disorder (OUD). The initiative is part of a broader effort to address the rising addiction crisis, which saw significant increases in overdose deaths in Kentucky and high prevalence rates in Ohio.
Pear Therapeutics announced the inclusion of its prescription digital therapeutics, reSET and reSET-O, on the January 2023 Florida Medicaid Preferred Drug List, effective January 1, 2023. This coverage allows Medicaid patients in Florida to access these innovative FDA-authorized treatments for substance use disorder and opioid use disorder. The state has approximately 5 million enrolled residents, making it the third largest Medicaid program. With nearly 2,000 overdose deaths in Florida in 2022, this initiative is a pivotal development in addressing the addiction crisis and improving treatment accessibility.
Pear Therapeutics, Inc. (NASDAQ: PEAR) will participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series on January 24 at 11:00 a.m. ET. Dr. Corey McCann, President and CEO, will discuss Pear's advancements in market access for its prescription digital therapeutics (PDTs).
Pear is a leader in developing software-based medicines, aiming to enhance patient care through clinically validated therapeutics. Their first PDT, reSET®, was the first to receive FDA marketing authorization for treating substance use disorder. The company has a strong pipeline, including reSET-O® and Somryst®, further solidifying its position in the digital health landscape.
The California Department of Health Care Services (DHCS) has selected Pear Therapeutics to implement the Recovery Incentives: California’s Contingency Management Program aiming to treat Medi-Cal members with stimulant use disorder. This pilot program will span 24 weeks and cover participants from 24 counties, followed by up to six months of recovery support. Pear will manage the electronic tracking and distribution of incentives. The initiative is viewed as a crucial step in expanding access to behavioral treatments for stimulant use disorders in California.
Pear Therapeutics (PEAR) has partnered with COEUS HealthCare to utilize the COEBRA™ platform for facilitating value-based contracts with state Medicaid programs for its prescription digital therapeutics (PDTs). This collaboration aims to streamline the reimbursement process and expand access to Pear’s products, reSET® and reSET-O®. The agreement supports the increasing demand for innovative solutions in treating mental health conditions and aligns with CMS’s push for value-based contracting guided by patient outcomes.
Pear Therapeutics, Inc. (NASDAQ: PEAR) has announced an expansion of its partnership with Spero Health to enhance patient access to its prescription digital therapeutics, reSET® and reSET-O®, for treating substance use disorder (SUD) and opioid use disorder (OUD). This collaboration aims to provide innovative treatment options at Spero's 99 locations across Indiana, Kentucky, Ohio, Tennessee, West Virginia, and Virginia. Previously implemented at 14 locations in Kentucky, this initiative seeks to increase patient engagement and improve recovery outcomes through effective technology integration.
